More recently a multicenter phase 1 clinical trial evaluated the effectiveness of atezolizumab (an anti-PD-L1 antibody) combined with bevacizumab (an anti-VEGF antibody) in the treatment of HCC (187). This evidence concerns the gene CD274 and hepatocellular carcinoma.